Group 2 Innate Lymphoid Cells in Health and Disease

Brian S. Kim1,2 and David Artis3

1Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110
2Center for the Study of Itch, Washington University School of Medicine, St. Louis, Missouri 63110
3Weill Cornell Medical College, Cornell University, New York, New York 10021

Correspondence: dartis@med.cornell.edu

Group 2 innate lymphoid cells (ILC2s) play critical roles in anti-helminth immunity, airway epithelial repair, and metabolic homeostasis. Recently, these cells have also emerged as key players in the development of allergic inflammation at multiple barrier surfaces. ILC2s arise from common lymphoid progenitors in the bone marrow, are dependent on the transcription factors RORγt, GATA3, and TCF-1, and produce the type 2 cytokines interleukin (IL)-4, IL-5, IL-9, and/or IL-13. The epithelial cell–derived cytokines IL-25, IL-33, and TSLP regulate the activation and effector functions of ILC2s, and recent studies suggest that their responsiveness to these cytokines and other factors may depend on their tissue environment. In this review, we focus on recent advances in our understanding of the various factors that regulate ILC2 function in the context of immunity, inflammation, and tissue repair across multiple organ systems.

Innate lymphoid cells (ILCs) are part of a family of innate immune cells that are heterogeneous in their expression of transcription factors and production of effector cytokines (Bjorkstrom et al. 2013; Spits et al. 2013). ILCs do not express cell lineage (Lin) markers associated with T cells, B cells, dendritic cells (DCs), macrophages, and granulocytes, but do express CD90 (Thy1 antigen), CD25 (interleukin [IL]-2Rα), and CD127 (IL-7Rα) (Spits et al. 2013). These cells are derived from a common lymphoid progenitor, and their development is dependent on the common γ-chain (γc or CD132), IL-7, Notch, and the transcription factor inhibitor of DNA binding 2 (Id2) (Yokota et al. 1999; Satoh-Takayama et al. 2010; Montecelli et al. 2011; Wong et al. 2012). More recent studies indicate that the majority of ILCs are also dependent on the transcriptional repressor PLZF and that all ILC subsets arise from a Lin−Id2+ CD127+ CD25− αβγ3+ precursor (Constantinides et al. 2014; Klose et al. 2014). ILCs are currently categorized into three distinct populations based on their differential developmental requirements, expression of defined transcription factors, and their expression of cell surface markers and effector cytokines (Spits and Cupedo 2012; Fuchs and Colonna 2013; Kim et al. 2013b; Spits et al. 2013, Walker et al. 2013): group 1 ILCs (ILC1s) include classical
NK cells and T-bet-dependent, IFN-γ-producing ILCs; RORγt- (Halim et al. 2012b; Wong et al. 2012), GATA3- (Hoyler et al. 2012; Klein et al. 2013), and TCF-1-dependent (Yang et al. 2013) group 2 ILCs (ILC2s) produce IL-4, IL-5, IL-9, IL-13, and/or amphiregulin (Monticelli et al. 2011); and RORγt-dependent group 3 ILCs (ILC3s) produce IL-17A and/or IL-22 (Fig. 1) (Sonnenberg and Artis 2012). These ILC populations are functionally analogous to the previously described Th1, Th2, and Th17 CD4⁺ T helper cell subsets, respectively. However, although ILCs exhibit shared functions with adaptive CD4⁺ T cells, they are unique in that they respond to innate signals in the absence of antigen specificity, lack T-cell receptors, and have distinct phenotypic and functional profiles.

Different subsets of ILCs promote either tissue homeostasis or detrimental inflammatory processes at multiple epithelial barrier surfaces (Monticelli et al. 2011; Sonnenberg et al. 2012; Hepworth et al. 2013; Qiu et al. 2013). Further, these cells have been implicated in a variety of different disease states including allergy, autoimmunity, cancer, infection, and obesity (Sonnenberg and Artis 2012; Kim et al. 2013b; Molofsky et al. 2013; Nussbaum et al. 2013). The roles of the ILC1 and ILC3 subsets in various diseases have been covered elsewhere (Spits and Cupedo 2012; Fuchs and Colonna 2013; Sonnenberg 2013; Sonnenberg et al. 2013; Spits et al. 2013). Therefore, in this review, we will focus primarily on the emerging role of ILC2s in both health and disease across multiple organ systems. First, we will introduce ILC2s and the context in which these cells were originally identified. Second, we will give an overview of the factors that broadly regulate ILC2s and their functions.

**Figure 1.** The innate lymphoid cell family. Innate lymphoid cells (ILCs) are a heterogeneous family of innate immune cells that arise from a common Id2-dependent lymphoid progenitor in the bone marrow. Group 1 ILCs (ILC1s) respond to IL-12 and IL-15, express the transcription factor T-bet, and produce tumor necrosis factor α (TNF-α) and interferon γ (IFN-γ). Group 2 ILCs (ILC2s) respond to IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), express the transcription factor GATA3, and produce IL-4, IL-5, IL-9, IL-13, and amphiregulin (Areg). Group 3 ILCs (ILC3s) respond to IL-23 and IL-1β, express the transcription factor RORγt, and produce IL-17A and IL-22.
known effector functions. Finally, we will discuss recent advances in our understanding of how ILC2s contribute to both homeostasis and inflammation in a tissue-specific and disease-oriented manner.

**IDENTIFICATION OF ILC2s**

ILC2s were originally identified as key contributors to the development of protective immunity to the parasite *Nippostrongylus brasiliensis* in the gut (Fort et al. 2001; Schmitz et al. 2005; Fallon et al. 2006; Moro et al. 2010; Neill et al. 2010; Price et al. 2010). In this context, ILC2s were found to be a critical source of IL-5 and IL-13, the latter of which promotes the induction of mucous secretion from goblet cells and smooth muscle contraction that contribute to anti-helminth immunity (Moro et al. 2010; Neill et al. 2010; Price et al. 2010). These studies were the first to uncover a previously unrecognized population of ILC2s that promotes type 2 cytokine-mediated immunity. Around the same time, an ILC2-like population, named multipotent progenitor type 2 (MPPtype2) cells, was also identified and shown to promote type 2 cytokine-mediated immunity to helminth infection (Saenz et al. 2010). Subsequently, MPPtype2 cells have been distinguished from ILC2s by their preferential responsiveness to IL-25 rather than IL-33, their progenitor-like phenotype, and their ability to differentiate into multiple granulocyte populations (Saenz et al. 2010). Subsequently, MPPtype2 cells have been distinguished from ILC2s by their preferential responsiveness to IL-25 rather than IL-33, their progenitor-like phenotype, and their ability to differentiate into multiple granulocyte populations (Saenz et al. 2010). Further, MPPtype2 cells exhibit distinct developmental requirements based on their Id2-independence, altered genome-wide transcriptional profiles from ILC2s, and their capacity to undergo extramedullary hematopoiesis (Saenz et al. 2013). Given that MPPtype2 cells and ILC2s are distinct populations, this review will focus specifically on the biology of ILC2s in the context of health and disease.

**REGULATION AND EFFECTOR FUNCTIONS OF ILC2s**

In the original studies that identified ILC2s, the epithelial cell-derived cytokines IL-25 and IL-33 were found to be potent activators of ILC2s, resulting in enhanced production of the key effector cytokines IL-5 and IL-13 (Fort et al. 2001; Schmitz et al. 2005; Fallon et al. 2006; Moro et al. 2010; Neill et al. 2010; Price et al. 2010). Subsequently, the predominantly epithelial cell–derived cytokine thymic stromal lymphopoietin (TSLP) has also been shown to be a key regulator of ILC2 function (Halim et al. 2012a; Kim et al. 2013a). Recent studies have shown that TSLP induces GATA3 expression in human ILC2s (Mjosberg et al. 2012) and promotes corticosteroid resistance to IL-33-mediated activation of ILC2s in the lung (Kabata et al. 2013). In addition, enforced expression of GATA3 in T cells and ILC2s results in elevated expression of IL-5 and IL-13 and enhanced susceptibility to allergic airway disease in mice (Kleinjan et al. 2014). These findings were consistent with prior studies by Mjosberg et al. showing that ectopic expression of GATA3 results in increased type 2 cytokine production in human ILC2s (Mjosberg et al. 2012). In addition to IL-5 and IL-13, in some circumstances, human and murine ILC2s can also produce the type 2 cytokines IL-4 and IL-9 (Wilhelm et al. 2011; Mjosberg et al. 2012; Doherty et al. 2013; Kleinjan et al. 2014). Recently, IL-9 has been shown to play a critical role in ILC2 survival in the context of lung infection with *N. brasiliensis* (Licona-Limon et al. 2013; Turner et al. 2013), suggesting that this ILC2 effector cytokine participates in a positive-feedback system. ILC2s are also a critical source of the epidermal growth factor receptor (EGFR) ligand Areg, which mediates lung epithelial repair following influenza infection (Monticelli et al. 2011). Although originally identified in association with lung ILC2s, Areg expression has also been shown in human skin ILC2s (Salimi et al. 2013). Taken together, these studies show that ILC2s are potently activated by the epithelial cell-derived cytokines IL-25, IL-33, and TSLP, and produce a variety of type 2 cytokines as well as the EGFR ligand Areg in mediating both immunity and epithelial repair (Fig. 2).

The regulation of ILC2 activation and acquisition of effector functions appears to involve a complex network of signals at the epithelial barrier surface. ILC2s are elicited by a
variety of factors such as microbial pathogens, helminth parasites, and allergens (Monticelli et al. 2012; Sonnenberg and Artis 2012). In addition to the epithelial cell–derived cytokines IL-25, IL-33, and TSLP, ILC2s express the receptors for and are activated by IL-2 (CD25) and IL-7 (CD127), indicating that they also respond to other stromal and hematopoietic cell-derived cytokines (Roediger et al. 2013). Further, ILC2s have also recently been shown to respond directly to non-cytokine molecules, including eicosanoids. Specifically, ILC2s are activated by prostaglandin D2 (PGD2) (Barnig et al. 2013; Chang et al. 2013; Xue et al. 2013) and leukotriene D4 (LTD4) (Doherty et al. 2013) and are inhibited by lipoxin A4 (LXA4) (Barnig et al. 2013). In addition to activation, human ILC2s express the PGD2 receptor chemoattractant receptor-homologous molecule expressed on T helper 2 cells (CRTH2) and migrate in vitro in response to PGD2 (Chang et al. 2013; Xue et al. 2013). Collectively, these studies show that ILC2s respond to a variety of signals that modulate both their cytokine production as well as chemotaxis (Fig. 2).

**ILC2s IN THE GUT**

ILC2s were originally identified in gastrointestinal tissue and fat-associated lymphoid clusters (FALCs), highlighting an important role for these cells in mediating protective immune responses and inflammation in the gut (Moro et al. 2010; Neill et al. 2010; Price et al. 2010). These original studies showed that IL-25- and IL-33-responsive ILC2s were critical for the development of type 2 cytokine–associated inflammation and goblet cell hyperplasia that facilitate expulsion of *N. brasiliensis* in the absence of adaptive immunity (Moro et al. 2010; Neill et al. 2010; Price et al. 2010). A more recent study has shown that IL-33 is critical for the induction of IL-13 production by ILC2s to mediate worm expulsion (Hung et al. 2013). In addition to their role in mediating protective immunity to helminth parasites, ILC2s also contribute to the development of pathologic type 2 inflammation, as they promoted gut inflammation in an IL-25-dependent fashion in a murine model of oxazalone-induced colitis (Camelo et al. 2012). In the context of food allergy, elevated IL-25, IL-33, and TSLP re-

<table>
<thead>
<tr>
<th>Human ILC2 response</th>
<th>Murine ILC2 response</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-25</td>
<td>IL-25</td>
</tr>
<tr>
<td>IL-33</td>
<td>IL-33</td>
</tr>
<tr>
<td>TSLP</td>
<td>TSLP</td>
</tr>
<tr>
<td>PGD2</td>
<td>LDL4</td>
</tr>
<tr>
<td>DR3</td>
<td>MHC II</td>
</tr>
<tr>
<td>CMKL1R</td>
<td>CysLT1R</td>
</tr>
<tr>
<td>FPR2/ALX</td>
<td>VPAC2</td>
</tr>
<tr>
<td>CRTH2</td>
<td>Amphiregulin</td>
</tr>
<tr>
<td>IL-4</td>
<td>IL-4</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>GM-CSF</td>
</tr>
<tr>
<td>IL-5</td>
<td>IL-5</td>
</tr>
<tr>
<td>Arginase-1</td>
<td>Arginase-1</td>
</tr>
<tr>
<td>IL-9</td>
<td>IL-9</td>
</tr>
<tr>
<td>IL13</td>
<td>IL13</td>
</tr>
</tbody>
</table>

Figure 2. Regulation of human and murine ILC2 responses. Human ILC2s are activated by IL-25, IL-33, TSLP, TL1A, and prostaglandin D2 (PGD2) and inhibited by lipoxin A4 (LXA4). Murine ILC2s are activated by IL-25, IL-33, TSLP, TL1A, leukotriene D4 (LTD4), and vasoactive intestinal peptide (VIP). Both human and murine ILC2s express the receptors to respond directly to these mediators and produce IL-4, IL-5, IL-9, IL-13, granulocyte macrophage colony–stimulating factor (GM-CSF), and amphiregulin (Areg). Murine ILC2s express arginase-1.
sponses have been observed in murine models and in patients (Blazquez et al. 2010; Herberth et al. 2010; Chu et al. 2013), provoking the hypothesis that these cytokines may promote ILC2 responses that contribute to the development of inflammation in the gut in response to food antigens through the expression of the type 2 cytokines IL-4, IL-5, and IL-13. However, the specific role of ILC2s in murine models of food allergy remains to be examined. Additionally, ILC2s have been characterized in human fetal gut and in the gut of healthy subjects as well as patients with inflammatory bowel disease (Mjosberg et al. 2011). However, accumulation of these cells in inflamed human intestinal tissue has not been shown. Further studies will be required to elucidate the role of ILC2s in promoting intestinal allergic inflammation in humans.

ILC2s IN THE RESPIRATORY TRACT

ILC2s and Influenza

Murine ILC2s in the lung were first described in murine models of influenza, where they were found to promote pathologic airway hyperreactivity (AHR) (Chang et al. 2011) as well as protective epithelial repair (Monticelli et al. 2011) in response to virus-induced lung inflammation. The latter study showed that ILC2s were a critical source of the EGFR ligand Areg in the lung following influenza virus infection, and treatment with recombinant Areg was sufficient to restore lung epithelial barrier integrity (Monticelli et al. 2011). A more recent study has shown that the interactions between ILC2s and NKT cells result in the production of IL-5 from ILC2s, which promotes the accumulation of eosinophils in the lung during the recovery phase of influenza infection (Gorski et al. 2013). However, the precise role of ILC2s in the pathogenesis of human influenza infection remains to be determined.

ILC2s and Allergic Airway Inflammation

Although ILC2s in the lung were first described in murine models of influenza (Chang et al. 2011; Monticelli et al. 2011), these cells have recently been shown to play a critical role in regulating the development of allergic airway inflammation. For example, IL-33-induced ILC2s that produce IL-13 contributed to the development of AHR in multiple murine asthma models in the absence of CD4+ T cells (Bar-temes et al. 2012; Beamer et al. 2012; Doherty et al. 2012; Kim et al. 2012; Salmond et al. 2012). Similarly, in models of allergen-induced airway inflammation, IL-25-, IL-33-, and TSLP-responsive ILC2s were critical for the development of allergic airway inflammation in lymphocyte-deficient mice (Halim et al. 2012a, 2012b; Klein et al. 2012). Although all of these studies showed that lung-resident ILC2s produce the effector cytokines IL-5 and IL-13, Wilhelm et al. further showed a critical role for ILC2-derived IL-9 in the context of papain-induced lung inflammation. Induction of allergic inflammation in IL-9 reporter mice revealed that ILC2s express IL-9 in an IL-2-dependent manner, which played a critical role in promoting the survival of ILC2s and in the induction of IL-5 and IL-13 expression (Wilhelm et al. 2011). A more recent study has also shown a critical role for IL-9 in mediating ILC2 survival in the lung during infection with N. brasiliensis (Turner et al. 2013).

Multiple reports indicate that IL-33 is a potent activator of IL-13-producing ILC2s in allergic airway inflammation (Bar-temes et al. 2012; Beamer et al. 2012; Mjosberg et al. 2012; Salmond et al. 2012; Hung et al. 2013; Shaw et al. 2013), but other epithelial cell-derived cytokines, bioactive lipids, and inflammatory factors also contribute to the development of pathogenic ILC2 responses in the lung. A recent study has shown that TSLP can contribute to ILC2 activation that promotes corticosteroid resistance in the context of IL-33-mediated airway inflammation (Kabata et al. 2013). Further, recent reports suggest that other factors, such as eicosanoids, could also play a key role in promoting ILC2 responses in the inflamed lung (Barnig et al. 2013; Doherty et al. 2013). For instance, lung ILC2s express the receptor for LTβ and ligation of this receptor rapidly induces IL-5 production by ILC2s. This process is abrogated by montelukast, a leukotriene recep-
tor antagonist used in the treatment of asthma (Doherty et al. 2013). In the same study, LTD₄, but not IL-33, induced high levels of IL-4 production by ILC2s (Doherty et al. 2013). Furthermore, in vitro studies have shown that PGD₂ derived from mast cells activates ILC2s, up-regulates expression of receptors for IL-25 (IL-17RA) and IL-33 (ST2), and induces chemotaxis of human ILC2s (Barnig et al. 2013; Chang et al. 2013; Xue et al. 2013). Furthermore, LXA₄, a proresolving factor known to be decreased in severe asthma, directly inhibited PGD₂-mediated activation of human ILC2s from peripheral blood (Xue et al. 2013). LXA₄ is an endogenous ligand for the receptor FPR2/ALX and functions to limit inflammation in asthma. Importantly, LXA₄ in conjunction with other proresolving receptors such as CMKLR1 was found to be expressed on human ILC2s, suggesting that these anti-inflammatory pathways may be operative on ILC2s (Barnig et al. 2013). Finally, two groups independently identified that the TNF-family cytokine TL1A promotes allergic airway inflammation and pathology in response to papain (Yu et al. 2013; Meylan et al. 2014), and that human peripheral blood ILC2s responded to asthma-associated PGD₂ by producing IL-13 (Barnig et al. 2013). In addition, pathogenic LTD₄-initiated lung ILC2 responses in mice were abrogated following treatment with montelukast (Doherty et al. 2013). Together, these studies suggest that ILC2s may be relevant targets in the treatment of asthma in patients. Further studies in human subjects will be required to determine whether ILC2s are directly pathogenic in human asthma and whether these cells could be targeted therapeutically.

**ILC2s and Other Lung Diseases**

Although the identification of ILC2s has generated significant interest in their role in allergic airway inflammation, ILC2s have been implicated in other pathologic pulmonary processes in humans. A recent study in patients with eosinophilic pleural effusion (EPE) associated with primary spontaneous pneumothorax (PSP) reported elevated expression of TSLP and IL-33 in the pleural fluid along with elevat-
ed IL-5, eotaxin-3, and enhanced ILC2 responses (Kwon et al. 2013). This study provokes the hypothesis that ILC2s may be the key driver of eosinophilia in the context of EPE and PSP. Another recent study used a Schistosoma mansoni egg-induced model of pulmonary fibrosis to identify that IL-25 is a key mediator of this disease in mice (Hams et al. 2014). Further investigation identified that IL-13-expressing ILC2s were both necessary and sufficient to induce pulmonary fibrosis in mice and that Lin<sup>−</sup>CD127<sup>−</sup>CRTH2<sup>+</sup>IL-33R<sup>−</sup>ILC2s were significantly enriched in the bronchial alveolar lavage fluid (BALF) of patients with idiopathic pulmonary fibrosis (IPF) (Hams et al. 2014). Collectively, these studies indicate that ILC2s may play different roles across multiple disease states in the lung including influenza, allergic airway disease, PSP, and IPF (Fig. 3).

### Chronic Rhinosinusitis

Chronic rhinosinusitis (CRS) is a common complication arising from allergic rhinitis and, when associated with nasal polyps, is strongly associated with type 2 cytokine production in the nasal mucosa. CRS was the first human disease in which an accumulation of Lin<sup>−</sup>CD127<sup>−</sup>CRTH2<sup>+</sup>ILC2s in inflamed tissue was clearly shown (Mjosberg et al. 2011). ILC2s in nasal polyps of CRS patients were originally identified as being responsive to IL-25 and IL-33, and were subsequently shown to respond to TSLP (Mjosberg et al. 2012). These studies also highlighted that human ILC2s produce IL-4, IL-5, IL-9, and IL-13, and express the TSLP receptor (TSLPR) (Mjosberg et al. 2012). A recent report confirmed that ILC2s are enriched in ethmoid sinus mucosa of pa-

---

**Figure 3.** Protective versus pathogenic roles of ILC2s. Gut-associated ILC2s play an essential role in protective immunity to helminth parasites and can promote type 2 inflammatory colitis. Lung ILC2s have shown a protective role by mediating epithelial repair in response to influenza virus infection. Further, they have shown pathogenic roles by promoting allergic airway disease, airway hyperreactivity, and pulmonary fibrosis and have been implicated in eosinophilic pleural effusion. ILC2s in the upper airway have been implicated in chronic rhinosinusitis and found in the nasal polyps of patients. Skin ILC2s are highly enriched in atopic dermatitis (AD) lesions and promote AD-like disease in murine models. ILC2s in the liver have been shown to promote tissue repair in response to viral-induced injury as well as pathogenic fibrosis. ILC2s in white adipose tissue regulate metabolic homeostasis via cellular interactions with eosinophils and alternatively activated macrophages.
tients with CRS and nasal polyps in comparison to control CRS patients without nasal polyps (Shaw et al. 2013). This study also showed that the ILC2s from CRS patients responded to IL-33-mediated stimulation by producing IL-13 (Shaw et al. 2013), further suggesting that ILC2s may contribute to the pathogenesis of allergic upper airway disease in humans. Consistent with previous findings (Mjosberg et al. 2012), TSLP has recently been shown to be highly expressed in the nasal polyps of CRS patients (Nagarkar et al. 2013). Although IL-33 appears to be more potent than TSLP in activating type 2 cytokine production from nasal polyp ILC2s (Mjosberg et al. 2012), further studies will be required to determine which cytokines optimally promote ILC2-mediated inflammation in CRS and whether these cells have a causal role in the development of nasal polyps or pathology in CRS patients.

ILC2s IN THE SKIN

Atopic Dermatitis

In addition to the role of ILC2s in promoting inflammation in the gut and lung, multiple studies have now shown that these cells also promote allergic inflammation in the skin. Lesional human AD skin has elevated expression of epithelial cell-derived cytokines that promote ILC2 responses including IL-25, IL-33, and TSLP (Soumelis et al. 2002; Hvid et al. 2011; Deleuran et al. 2012; Savinko et al. 2012), and ILC2s have been identified in both murine and human skin and are enriched in the lesional skin of human AD patients (Kim et al. 2013a; Roediger et al. 2013). Although IL-33 has emerged as the dominant cytokine in the activation of ILC2s from murine lung (Barlow et al. 2013), human blood, and nasal polyps (Mjosberg et al. 2012), the original studies identifying skin ILC2s found that murine skin ILC2s are IL-33- and IL-25-independent but dependent on TSLP for their activation during murine AD-like disease (Kim et al. 2013a). Further, skin-associated ILC2s could directly induce AD-like pathology and T112 cell responses in vivo (Kim et al. 2013a). A more recent study confirmed the presence of ILC2s in murine skin and used transgenic mice overexpressing IL-33 under a keratin 14 promoter to show that IL-33 expression can also drive AD-like inflammation and the expansion of ILC2s in the skin (Imai et al. 2013). Recently, Salimi et al. (2013) confirmed that skin ILC2s are dependent on TSLP in C57BL/6 mice and found that there is partial dependence on both IL-25 and IL-33 in the development of skin ILC2 responses in BALB/c (but not C57BL/6) mice during AD-like inflammation. They also showed the presence of ILC2s in human skin and their enrichment in lesional AD skin (Salimi et al. 2013). Further, they found that human skin ILC2s up-regulate expression of both type 2 cytokines and Areg in response to IL-33 (Salimi et al. 2013). Finally, recent work has also focused on the cellular interactions and migratory patterns of skin ILC2s. Roediger et al. used intravital multiphoton microscopy to directly visualize skin ILC2s and characterize their interactions with skin-resident mast cells (Roediger et al. 2013). In these studies, skin ILC2s were found to constitutively express IL-13, produce IL-5 in response to IL-2-mediated activation, and modulate cutaneous mast cell responses (Roediger et al. 2013). Collectively, these studies show that skin ILC2s promote type 2 cytokine–associated skin inflammation and coordinately interact with other innate and adaptive cells in the skin to influence their function (Fig. 4). However, further studies will be required to fully assess the factors that promote and regulate ILC2-mediated skin inflammation.

ILC2s IN METABOLIC TISSUES

ILC2s in the Liver

Although the importance of ILC2 responses at mucosal barriers such as the gut and lung has been appreciated, ILC2 responses have also been characterized in other organs that regulate metabolic homeostasis such as the liver and adipose tissue. The liver is a critical regulator of glucose metabolism, whereas the adipose tissue is a regulator of lipid homeostasis. In the context of liver disease, patients with cir-
rhosis and mice with CCL4-induced hepatic fibrosis had significantly higher levels of IL-33 in the serum in comparison to controls (McHedlidze et al. 2013). Based on these findings, McHedlidze et al. (2013) showed that IL-33 mediates hepatic fibrogenesis in mice via ILC2s. They also identified that human cirrhotic livers have higher expression of IL-13 receptor components, suggesting that ILC2-derived IL-13 may be a key mediator of hepatic fibrosis in humans as well (McHedlidze et al. 2013). Another recent study identified that IL-33 attenuates liver damage in the context of adenovirus-induced hepatitis in mice, possibly through the ability of IL-33-dependent ILC2s to limit TNF-α production from hepatic T cells and macrophages (Liang et al. 2013). Adoptive transfer studies also suggested that ILC2s might mediate liver protection in vivo in response to viral hepatitis (Liang et al. 2013). However, the precise mechanisms by which ILC2s are protective in the liver remain to be determined. Collectively, these studies indicate that IL-33-dependent ILC2s can have either beneficial or detrimental effects on liver homeostasis depending on the context of liver injury (Fig. 3). Future studies will be required to determine the effector mechanisms by which ILC2s mediate these processes.

**ILC2s in White Adipose Tissue**

Recent work has highlighted a previously unappreciated role for ILC2s in mediating metabolic homeostasis in adipose tissue. Type 2 cytokine-associated eosinophil responses regulate AAMs to promote glucose and adipose tissue homeostasis (Wu et al. 2011) and ILC2s have recently been shown to regulate this process via production of IL-5 and its effect on eosinophil survival (Fig. 4) (Molofsky et al. 2013). In support of these findings, IL-33 was shown to limit obesity in mice (Miller et al. 2010), whereas another study showed that IL-25 elicits ILC2s to limit obesity (Hams et al. 2013). Similarly, depletion of ILC2s led to enhanced weight gain in lymphocyte-deficient Rag1−/− mice and loss of eosinophil and AAMs populations in the visceral adipose tissue (VAT) in response to a high fat diet (Hams et al. 2013; Molofsky et al. 2013). These findings were further explored in a study by Nussbaum et al., which reported that serum levels of IL-5 and blood eosinophils correlated with circadian variation (Nussbaum et al. 2013). In addition, this study showed that ILC2 responses in the small intestine were enhanced in response to caloric input as determined by IL-13 expression (Nussbaum et al. 2013), suggesting that ILC2s may respond di-

---

**Figure 4.** Effector functions of ILC2s. ILC2s in the lung have been proposed to promote adaptive CD4+ T-cell and B-cell responses via MHC class II–mediated antigen presentation and IL-6 production, respectively. Further, IL-13 has been shown to promote CD4+ T-cell responses indirectly via acting on dendritic cells. ILC2-derived IL-5 promotes eosinophil responses and IL-13 can regulate alternatively activated macrophage and mast cell functions.
rectly to signals that regulate feeding and circadian rhythms. In support of this hypothesis, ILC2s were shown to express VPAC2, the receptor for vasoactive intestinal peptide (VIP), a neuropeptide that is abundant in the intestine and tightly regulated by both feeding and circadian rhythms. Additionally, ILC2s were shown to produce IL-5 in response to both VIP and a VPAC2 agonist in vitro (Nussbaum et al. 2013). Collectively, these studies suggest that metabolic and circadian cues can influence ILC2 responses and their production of IL-5 and IL-13, which in turn regulate eosinophils and AAMs in the context of metabolic homeostasis (Fig. 4). Further studies will be required to fully dissect the mechanisms by which ILC2 responses regulate metabolic homeostasis and contribute to the development of various metabolic diseases.

CONCLUSIONS AND FUTURE DIRECTIONS

Originally described in the context of anti-helminth immunity, ILC2s appear to have diverse functions at multiple barrier surfaces including the upper and lower airways, skin, and gut (Fig. 3) (Tait W ojno and Artis 2012). Further, ILC2s have also been identified in multiple other tissues including the brain, heart, kidney, muscle, liver, and adipose tissue (Hams et al. 2013; Liang et al. 2013; McHedlidze et al. 2013; Molofsky et al. 2013; Nussbaum et al. 2013). However, there are a number of questions that remain regarding the function of ILC2s. For example, the potential tissue-specific factors that regulate ILC2s are complex and remain poorly understood. The current body of evidence suggests that IL-33 may be the dominant cytokine for the activation of lung and airway ILC2s (Mjosberg et al. 2012; Monticelli et al. 2012; Barlow et al. 2013), whereas IL-25 is critical for their role in gut inflammation (Camelo et al. 2012). However, IL-25 may also play a role in the regulation of pulmonary fibrosis (Hams et al. 2014). In the skin, ILC2s have been shown to be predominantly regulated by TSLP during AD-like disease (Kim et al. 2013a). However, recent studies showed that IL-25 and IL-33 may also have relevant roles in AD-like inflammation (Imai et al. 2013; Salimi et al. 2013). Collectively, whether IL-25, IL-33, or TSLP is the dominant cytokine for the activation and/or elicitation of ILC2s at different barrier surfaces remains to be determined.

Beyond epithelial cell–derived cytokine regulation, ILC2 activation and migration also appear to be regulated by other factors, such as TL1A (Yu et al. 2013; Meylan et al. 2014) and eicosanoids (Barnig et al. 2013; Chang et al. 2013; Doherty et al. 2013; Xue et al. 2013) in the intestine and lung, respectively. In the intestine, VIP, which is heavily influenced by caloric intake and circadian rhythms, has also been shown to activate cytokine production from ILC2s (Nussbaum et al. 2013). Furthermore, ILC2s are a novel source of growth factors (e.g., Areg) and enzymes (e.g., Arg1) that may regulate epithelial repair and inflammation at barrier surfaces (Monticelli et al. 2011; Bando et al. 2013). These newer studies show that the regulation and function of ILC2s may be much more complex than previously recognized.

Moreover, recent studies have shown that ILC2s interact with and/or regulate other innate cell populations such as mast cells (Roe-diger et al. 2013), eosinophils (Nussbaum et al. 2013), and macrophages (Molofsky et al. 2013), as well as adaptive T112 cell responses via type 2 cytokine–mediated activation of DCs (Fig. 4) (Halim et al. 2014). Additionally, MHC class II–mediated antigen presentation by ILC2s has been recently shown to induce CD4+ T cell proliferation (Mirchandani et al. 2014). Thus, understanding how ILC2s regulate type 2 cytokine–associated inflammation through interactions with various innate and adaptive cell populations is an emerging field of great interest. Further, the role ILC2s play in food allergy and other allergic diseases that influence epithelial barriers, such as urticaria, eosinophilic gastrointestinal diseases, and anaphylaxis, remains to be explored. Future studies aimed at understanding the regulation and effector mechanisms of human ILC2s in different organ systems will be critical to developing therapeutics that target ILC2s to treat multiple inflammatory diseases.
Group 2 Innate Lymphoid Cells


Herbert G, Daegelmann C, Roder S, Behrendt H, Kramer U, Borte M, Heinrich J, Herbarth O, Lehmann I. 2010. IL-17E but not IL-17A is associated with allergic sensitiza-
B.S. Kim and D. Artis


Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, Furusawa J, Ohtani M, Fuji H, Koyasu S. 2010. Innate production of Tg1 cytokines by adipose tissue-
Group 2 Innate Lymphoid Cells

B.S. Kim and D. Artis


Group 2 Innate Lymphoid Cells in Health and Disease
Brian S. Kim and David Artis

Cold Spring Harb Perspect Biol published online January 8, 2015

Subject Collection  Innate Immunity and Inflammation

Group 2 Innate Lymphoid Cells in Health and Disease
Brian S. Kim and David Artis

Inflammation and the Blood Microvascular System
Jordan S. Pober and William C. Sessa

Sinusoidal Immunity: Macrophages at the Lymphohematopoietic Interface
Siamon Gordon, Annette Plüddemann and Subhankar Mukhopadhyay

Allergic Inflammation—Innately Homeostatic
Laurence E. Cheng and Richard M. Locksley

Approaching the Next Revolution? Evolutionary Integration of Neural and Immune Pathogen Sensing and Response
Kevin J. Tracey

Inflammasomes
Marcel R. de Zoete, Noah W. Palm, Shu Zhu, et al.

IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka, Masashi Narazaki and Tadamitsu Kishimoto

The Chemokine System in Innate Immunity
Caroline L. Sokol and Andrew D. Luster

Microbial Sensing by Toll-Like Receptors and Intracellular Nucleic Acid Sensors
Surya Pandey, Taro Kawai and Shizuo Akira

Tumor Necrosis Factor Superfamily in Innate Immunity and Inflammation
John Sedý, Vasileios Bekiaris and Carl F. Ware

Emerging Principles Governing Signal Transduction by Pattern-Recognition Receptors
Jonathan C. Kagan and Gregory M. Barton

Lipid Mediators in the Resolution of Inflammation
Charles N. Serhan, Nan Chiang, Jesmond Dalli, et al.

Transcriptional Control of Inflammatory Responses
Stephen T. Smale and Gioacchino Natoli

DNA Degradation and Its Defects
Kohki Kawane, Kou Morani and Shigekazu Nagata

For additional articles in this collection, see http://cshperspectives.cshlp.org/cgi/collection/

Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved